Virios Therapeutics announced that the World Intellectual Property Organization has published Virios’ global patent application titled “Valacyclovir and Celecoxib for the Treatment of Alzheimer’s and COVID-19”, which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIRI:
- Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Virios Therapeutics expects resources to fund operations into 4Q24
- Virios Therapeutics reports Q4 EPS (6c) vs. (11c) last year
- Virios Therapeutics announces director fee, management team salary cut
- Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones